BP’s 10x Genomics TXG Stock Holding History

BP’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,564	Closed	-$306K	–	494
2021 Q2	$306K	Hold	1,564	–	–	0.01%	536
2021 Q1	$283K	Buy	+1,564	New	+$270K	0.01%	564

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BP's TXG Position: Q3 2021 in Review

BP sold out of 10x Genomics (TXG) in Q3 2021, closing a stake of 1,564 shares — an estimated $306K sold.

BP first reported a position in TXG in Q1 2021 and held it in 2 quarters. The position peaked at $306K in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

BP reported no remaining 10x Genomics position as of Q3 2021 after selling out during the quarter.
BP sold 1,564 10x Genomics shares in Q3 2021, an estimated $306K.
BP first reported a position in 10x Genomics in Q1 2021 and held it in 2 quarters.
BP's 10x Genomics position peaked at $306K in Q2 2021.
330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on BP's 13F filing for Q3 2021, filed 10 Nov 2021.